机构:
Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cell Signaling, IL-91904 Jerusalem, IsraelHebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cell Signaling, IL-91904 Jerusalem, Israel
Levitzki, A
[1
]
机构:
[1] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cell Signaling, IL-91904 Jerusalem, Israel
EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a rote in lung cancers, with special emphasis on the way EGFR/ Her-2 signaling cooperates with other signaling pathways. (C) 2003 Elsevier Science Ireland Ltd and Ainerican Society of Clinical Oncology. Published by Elsevier Science Ireland Ltd. All rights reserved.
机构:
Univ Oklahoma, Stephenson Canc Ctr, Hematol Oncol Sect, Oklahoma City, OK USAUniv Oklahoma, Stephenson Canc Ctr, Hematol Oncol Sect, Oklahoma City, OK USA
Tripathi, Abhishek
Gupta, Shilpa
论文数: 0引用数: 0
h-index: 0
机构:
Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USAUniv Oklahoma, Stephenson Canc Ctr, Hematol Oncol Sect, Oklahoma City, OK USA
机构:
Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA
Harvard Univ, Sch Med, Boston, MA 02215 USAJohns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA